HER2-low status in inflammatory breast cancer (IBC) is associated with hormone receptors positivity but not with pathological response to neoadjuvant chemotherapy or overall survival

被引：0
|
作者：
de Nonneville, Alexandre
Finetti, Pascal
Boudin, Laurys
Usclade, Lucas
Viens, Patrice
Viret, Frederic
Mamessier, Emilie
Goncalves, Anthony
Bertucci, Francois
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-02-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-02-07
引用
收藏
页数：3
相关论文
共 50 条
  • [1] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    de Moura Leite, Luciana
    Cesca, Marcelle Goldner
    Tavares, Monique Celeste
    Santana, Debora Maciel
    Saldanha, Erick Figueiredo
    Guimaraes, Paula Tavares
    Sa, Daniella Dias Silva
    Simoes, Maria Fernanda Evangelista
    Viana, Rafael Lima
    Rocha, Francisca Giselle
    Loose, Simone Klog
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla Albina Zanco
    Mattos, Bruna Raphaeli Silva
    Campos, Fernando Augusto Batista
    Sanches, Solange Moraes
    de Lima, Vladmir Claudio Cordeiro
    Ponde, Noam Falbel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (01) : 155 - 163
  • [2] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    Luciana de Moura Leite
    Marcelle Goldner Cesca
    Monique Celeste Tavares
    Debora Maciel Santana
    Erick Figueiredo Saldanha
    Paula Tavares Guimarães
    Daniella Dias Silva Sá
    Maria Fernanda Evangelista Simões
    Rafael Lima Viana
    Francisca Giselle Rocha
    Simone Klog Loose
    Sinara Figueiredo Silva
    Rafaela Pirolli
    Camilla Albina Zanco Fogassa
    Bruna Raphaeli Silva Mattos
    Fernando Augusto Batista Campos
    Solange Moraes Sanches
    Vladmir Cláudio Cordeiro de Lima
    Noam Falbel Pondé
    Breast Cancer Research and Treatment, 2021, 190 : 155 - 163
  • [3] Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer
    Qiao, Weiqiang
    Guo, Wanying
    Liu, Qipeng
    Guo, Xiao
    Deng, Miao
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2023, 64
  • [4] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wei Wang
    Tingting Zhu
    Hao Chen
    Yongzhong Yao
    Clinical and Translational Oncology, 2023, 25 : 1673 - 1681
  • [5] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wang, Wei
    Zhu, Tingting
    Chen, Hao
    Yao, Yongzhong
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (06): : 1673 - 1681
  • [6] Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients
    Guan, Dandan
    Shi, Qingyang
    Zheng, Yajuan
    Zheng, Chaopeng
    Meng, Xuli
    CLINICAL BREAST CANCER, 2024, 24 (05) : 463 - 472.e2
  • [7] Impact of HER2-Low Status on Pathologic Complete Response and Survival Outcome Among Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
    Lee, Young Joo
    Yoo, Tae-Kyung
    Lee, Sae Byul
    Chung, Il Yong
    Kim, Hee Jeong
    Ko, Beom Seok
    Lee, Jong Won
    Son, Byung Ho
    Ahn, Sei Hyun
    Jeong, Hyehyun
    Jung, Jae Ho
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Kim, Sung-Bae
    Lee, Hee Jin
    Gong, Gyungyub
    Kim, Jisun
    JOURNAL OF BREAST CANCER, 2025, 28 (01) : 11 - 22
  • [8] Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
    Ilie, Silvia Mihaela
    Briot, Nathalie
    Constantin, Guillaume
    Roussot, Nicolas
    Ilie, Alis
    Bergeron, Anthony
    Arnould, Laurent
    Beltjens, Francoise
    Desmoulin, Isabelle
    Mayeur, Didier
    Kaderbhai, Coureche
    Hennequin, Audrey
    Jankowski, Clementine
    Padeano, Marie Martine
    Costaz, Helene
    Amet, Alix
    Coutant, Charles
    Coudert, Bruno
    Bertaut, Aurelie
    Ladoire, Sylvain
    BREAST CANCER, 2023, 30 (06) : 997 - 1007
  • [9] Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
    Silvia Mihaela Ilie
    Nathalie Briot
    Guillaume Constantin
    Nicolas Roussot
    Alis Ilie
    Anthony Bergeron
    Laurent Arnould
    Françoise Beltjens
    Isabelle Desmoulin
    Didier Mayeur
    Courèche Kaderbhai
    Audrey Hennequin
    Clémentine Jankowski
    Marie Martine Padeano
    Helène Costaz
    Alix Amet
    Charles Coutant
    Bruno Coudert
    Aurélie Bertaut
    Sylvain Ladoire
    Breast Cancer, 2023, 30 : 997 - 1007
  • [10] HER2-low inflammatory breast cancer (IBC): Clinicopathologic features and prognostic implications
    Tarantino, P.
    Niman, S. L.
    Erick, T.
    Priedigkeit, N.
    Harrison, B.
    Giordano, A.
    Nakhlis, F.
    Bellon, J. R.
    Parker, T.
    Strauss, S.
    Jin, Q.
    King, T. A.
    Overmoyer, B.
    Curigliano, G.
    Regan, M.
    Tolaney, S.
    Lynce, F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S629 - S630
12345